{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:05:34Z","timestamp":1792785934437,"version":"4.5.0"},"reference-count":18,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Chinese Health Promotion Foundation IBD Research Fund Technology","award":["KYGYJJ-2"],"award-info":[{"award-number":["KYGYJJ-2"]}]},{"name":"Xi\u2019an Municipal Bureau of Science and Technology Medical Research","award":["2026JH-YXYM-0016"],"award-info":[{"award-number":["2026JH-YXYM-0016"]}],"id":[{"id":"https:\/\/ror.org\/006mtxa58","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In real-world clinical settings, direct comparative evidence on the effectiveness of infliximab vs vedolizumab for biologic-na\u00efve patients with moderate-to-severe ulcerative colitis remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective, multicenter, real-world study enrolled patients with moderate-to-severe ulcerative colitis who were biologic-na\u00efve and began using infliximab or vedolizumab from January 2023 to November 2024. To reduce confounding, inverse probability of treatment weighting was applied. The primary outcome was a composite of 14-week clinical remission and 52-week endoscopic remission. The secondary endpoints encompassed clinical response\/remission, endoscopic response\/remission, and clinical steroid-free remission at weeks 14 and 30; clinical remission, endoscopic remission, and clinical steroid-free remission at week 52; and the therapeutic continuation rate and adverse events rate across the complete observation period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 251 eligible patients were enrolled. After inverse probability of treatment weighting, vedolizumab was significantly superior to infliximab for the composite endpoint (60.18% vs 39.52%; P\u2009=\u2009.003). Significantly greater proportions of patients in the vedolizumab group attained clinical remission (84.80% vs 66.49%; P\u2009=\u2009.003), steroid\u2011free clinical remission (75.87% vs 59.57%; P\u2009=\u2009.015), endoscopic response (70.43% vs 52.44%; P\u2009=\u2009.008), and endoscopic remission (70.43% vs 52.44%; P\u2009=\u2009.008) at week 14 relative to the infliximab group. Effectiveness endpoints were comparable between groups at week 30. At week 52, vedolizumab remained significantly superior in clinical remission (78.39% vs 57.38%; P\u2009=\u2009.003), clinical steroid-free remission (75.96% vs 53.39%; P\u2009=\u2009.002), and endoscopic remission (66.03% vs 51.12%; P\u2009=\u2009.042). The rate of adverse events did not differ significantly between the vedolizumab and infliximab groups (5.47% vs 7.57%; P\u2009=\u2009.56).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among patients with moderate-to-severe ulcerative colitis who have not been treated with biologics before, vedolizumab-first therapy showed superior short- and long-term effectiveness vs infliximab-first therapy, with comparable safety profiles. Vedolizumab could serve as the initial biologic agent for moderate\u2011to\u2011severe ulcerative colitis.<\/jats:p>\n                    <jats:p>NCT06962020; Selection and Efficacy-Inducing Factors of First-Line Biologic Agents in Moderate-to-Severe Ulcerative Colitis; https:\/\/clinicaltrials.gov\/study\/NCT06962020<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izag185","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:02:10Z","timestamp":1789473730000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparative effectiveness of infliximab vs vedolizumab as first-line biologic therapy in moderate-to-severe ulcerative colitis: A prospective, multicenter, real-world study"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1812-9951","authenticated-orcid":false,"given":"Dongdong","family":"He","sequence":"first","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Department of Gastroenterology & Hepatology, Xijing Hospital, The Fourth Military Medical University , Xi\u2019an,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumei","family":"Sha","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Second Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Insurance, Xijing Hospital, The Fourth Military Medical University , Xi\u2019an,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Ankang Central Hospital , Ankang,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Qu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Department of Gastroenterology & Hepatology, Xijing Hospital, The Fourth Military Medical University , Xi\u2019an,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Second Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Department of Gastroenterology & Hepatology, Xijing Hospital, The Fourth Military Medical University , Xi\u2019an,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Feng","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Department of Gastroenterology & Hepatology, Xijing Hospital, The Fourth Military Medical University , Xi\u2019an,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Department of Gastroenterology & Hepatology, Xijing Hospital, The Fourth Military Medical University , Xi\u2019an,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Department of Gastroenterology & Hepatology, Xijing Hospital, The Fourth Military Medical University , Xi\u2019an,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongquan","family":"Shi","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Department of Gastroenterology & Hepatology, Xijing Hospital, The Fourth Military Medical University , Xi\u2019an,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3004-2634","authenticated-orcid":false,"given":"Min","family":"Chen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Department of Gastroenterology & Hepatology, Xijing Hospital, The Fourth Military Medical University , Xi\u2019an,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"2026092314070250400_izag185-B1","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Le Berre","year":"2023","journal-title":"Lancet"},{"key":"2026092314070250400_izag185-B2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.dld.2024.08.044","article-title":"Disease burden of patients with moderate to severe ulcerative colitis: a French multicenter real-life study (THEFAR)","volume":"57","author":"Fumery","year":"2025","journal-title":"Dig Liver Dis"},{"key":"2026092314070250400_izag185-B3","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/j.cgh.2024.08.047","article-title":"Multidimensional patient-reported outcomes and quality of life at diagnosis of IBD: a population-based inception cohort study","volume":"23","author":"Attauabi","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026092314070250400_izag185-B4","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.cgh.2024.06.050","article-title":"Modern advanced therapies for inflammatory bowel diseases: practical considerations and positioning","volume":"23","author":"Fudman","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026092314070250400_izag185-B5","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"2026092314070250400_izag185-B6","doi-asserted-by":"publisher","first-page":"101994","DOI":"10.1016\/j.bpg.2025.101994","article-title":"Treatment sequencing in inflammatory bowel disease: Towards clinical precision medicine","volume":"77","author":"Sequier","year":"2025","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2026092314070250400_izag185-B7","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1053\/j.gastro.2024.10.001","article-title":"AGA Living Clinical Practice Guideline on pharmacological management of moderate-to-severe ulcerative colitis","volume":"167","author":"Singh","year":"2024","journal-title":"Gastroenterology"},{"key":"2026092314070250400_izag185-B8","doi-asserted-by":"publisher","first-page":"17562848241281218","DOI":"10.1177\/17562848241281218","article-title":"Comparison of clinical and endoscopic efficacy between vedolizumab and infliximab in bio-na\u00efve patients with ulcerative colitis: a multicenter, real-world study","volume":"17","author":"Huang","year":"2024","journal-title":"Ther Adv Gastroenterol"},{"key":"2026092314070250400_izag185-B9","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1038\/s41598-023-28907-3","article-title":"Vedolizumab is superior to infliximab in biologic na\u00efve patients with ulcerative colitis","volume":"13","author":"Sablich","year":"2023","journal-title":"Sci Rep"},{"key":"2026092314070250400_izag185-B10","doi-asserted-by":"publisher","first-page":"502396","DOI":"10.1016\/j.gastrohep.2025.502396","article-title":"Clinical effectiveness and safety of vedolizumab versus infliximab in biologic-na\u00efve patients with ulcerative colitis: A comparative real-world multicentric observational study","volume":"48","author":"da Costa Ferreira","year":"2025","journal-title":"Gastroenterol Hepatol"},{"key":"2026092314070250400_izag185-B11","doi-asserted-by":"publisher","first-page":"17562848221080793","DOI":"10.1177\/17562848221080793","article-title":"Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study","volume":"15","author":"Pudipeddi","year":"2022","journal-title":"Ther Adv Gastroenterol."},{"key":"2026092314070250400_izag185-B12","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/apt.17616","article-title":"Real-world effectiveness of vedolizumab compared with anti-TNF agents in biologic-na\u00efve patients with ulcerative colitis: A two-year propensity-score-adjusted analysis from the prospective, observational VEDOIBD -study","volume":"58","author":"Bokemeyer","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"2026092314070250400_izag185-B13","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/1751-2980.13270","article-title":"Effectiveness and safety of vedolizumab and infliximab in biologic-na\u00efve patients with moderate-to-severe ulcerative colitis: A multicenter, retrospective cohort study","volume":"25","author":"Meng","year":"2024","journal-title":"J Dig Dis"},{"key":"2026092314070250400_izag185-B14","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/ecco-jcc\/jjad203","article-title":"Biologic therapy for inflammatory bowel disease: real-world comparative effectiveness and impact of drug sequencing in 13 222 patients within the UK IBD BioResource","volume":"18","author":"Kapizioni","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026092314070250400_izag185-B15","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/apt.18441","article-title":"Long-term outcomes of an infliximab-first versus vedolizumab-first treatment strategy in biologic-na\u00efve patients with ulcerative colitis","volume":"61","author":"Haynesworth","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"2026092314070250400_izag185-B16","author":"National Cancer Institute","year":"2017"},{"key":"2026092314070250400_izag185-B17","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"2026092314070250400_izag185-B18","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izag185\/71354419\/izag185.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izag185\/71354419\/izag185.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:07:06Z","timestamp":1790186826000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article\/doi\/10.1093\/ibd\/izag185\/8832387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":18,"URL":"https:\/\/doi.org\/10.1093\/ibd\/izag185","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"article-number":"izag185"}}